Canopy Growth Reports Q3 FY2025 Results: Revenue Down 5%, Adjusted EBITDA Improves 61%

Canopy Growth Corp

2025-Q3 EPS reported -$4.09 vs consensus -$0.16 ▼ miss (-2437.2%)

Net revenue was $74.8M, down 5% YoY but up 8% excluding divestitures.
Canada medical cannabis net revenue rose 16% to $19.6M; Storz & Bickel revenue up 19% to $22M.
Adjusted EBITDA loss improved 61% to $3.5M; net loss from continuing operations was $121.9M.
Total debt reduced to $442M from $554M at September 30, 2024, after early term loan prepayment.
Claybourne infused pre-rolls launched in Canada, reaching #3 market share in BC and Ontario within 6 weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.